Fig. 1From: Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLCStudy flow diagram. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; single T, EGFR-TKI monotherapy; A+T, Avastin (bevacizumab) combined with EGFR-TKIBack to article page